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self-reported and prescription-only data, acetaminophen was
increased by OA, and unrelated to sex and age after controlling
for OAD. In both datasets, NSAIDs were increased by OAD and
older age, and unrelated to sex. Medication use is higher in
self-reported versus prescription-only data. However, effects are
similar, thus large prescription databases may be advantageous
even for medications with nonprescription forms.
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OBJECTIVE: Drugs used in severe status failed in previous treat-
ment are necessary for small target patients even though they are
expensive to cover. However, it’s difﬁcult to assess whether they
should be listed on reimbursement, because most have little
evidence including clinical trial and economic evaluation. There-
fore we analyzed previous submissions to ﬁnd out characteristics
of those drugs. METHODS: We investigated characteristics of 13
submissions of no alternative drugs for reimbursement decision
from 2003 to 2007 in Korea and those drugs’ reimbursement
decisions in other countries. RESULTS: Three drugs (23%) had
high level evidence based on SR and RCT, and 11 drugs were
recommended in clinical guidelines. Eight economic evaluations
(62%) were submitted. Mean additional survival duration was
5.35 month (range 0.8 to 11.1) when life year gained is presented
as outcome value (N = 7, 54%). Two of them compared with
best supportive care or placebo showed ICER was 1.10 GDP/
LYG (0.57 to 1.64) and the others compared with standard
therapy showed lower value of ICER (0.86 GDP/LYG, -0.09 to
2.07). Average net amount of budget impact was 9 million USD
(431 thousand to 44 million USD). Drugs compared with BSC
were almost decided not to be reimbursed except for one drug
having longer additional survival, less ICER and lower budget
impact. On the contrary, those compared with standard therapy
were reimbursed except for one drug having higher ICER(2.07
GDP/LYG) and budget impact. Some drug having low efﬁciency
but low budget impact was listed in Korea. Decisions for reim-
bursement about those drugs were not consistent among
countries (Austrailia, UK, Canada and Korea). CONCLUSION:
Additional life year gained, efﬁciency and budget impact seemed
to affect reimbursement decision in Korea. Further investigation
is required for setting of criteria in reimbursement evaluation of
no alternative drugs, especially having good cost-effectiveness
and high budget impact or the opposite.
PMS44
PRESCRIPTIONTREATMENT PATTERNS IN PATIENTSWITH
CHRONIC OSTEOARTHRITIS PAIN
Ng DB1, Mackowiak J2, Slaton T2, Mody S1, Benson C1
1Ortho-McNeil Janssen Scientiﬁc Affairs, LLC, Raritan, NJ, USA,
2Center for Outcomes Research, Chapel Hill, NC, USA
OBJECTIVE: Describe current treatment patterns in patients
(pts) with chronic osteoarthritis (OA) pain, with emphasis on
their opioid therapy. METHODS: Using a large 2006 commer-
cial claims database, continuously enrolled adult OA pts (ICD-9
CM code = 715.XX, 18 years old) with chronic non-
malignant pain were identiﬁed. Those with at least 120 days
supply (ds) of pain medication in 2006 were classiﬁed as having
“chronic pain.” Pts were grouped based on their use of con-
trolled long acting opioids (LAO), controlled short acting
opioids (SAO), and all other non-controlled analgesics. Pt
demographics, comorbidities, and drug utilization were exam-
ined. RESULTS: Of the over 8 million pts in the claims data-
base, 33,221 pts (mean age 54.4; 64.5% female) had “chronic
OA pain.” The most common comorbidities were hypertension
(55.9%), hypercholesterolemia (51.2%), diabetes (19.7%), and
GERD (17.5%). The most common pain-related medications
used were NSAIDs (71.4%), controlled (CII-CIII) opioids
(71.0%), antidepressants (42.5%), anti-ulcer drugs (39.7%),
and musculoskeletal therapy agents (30.0%). Nearly half of pts
(48.1%) had claims for 30 ds of a controlled opioid for pain,
40.3% with 60 ds, and 35.8% with 90 ds of controlled
opioids for pain in 2006. Eleven percent (11%) were prescribed
an LAO (CII-CIII), with 7.7% (2,559/33,221) used a SAO as
monotherapy for pain with least a 120 ds in 2006. Stated dif-
ferently, 12.8% (2,559/19,946) of SAO users and 34.3%
(1,253/3,653) of LAO users did not have a claim for a non-
controlled analgesic utilizing only opioids for prescription pain
control. CONCLUSION: Almost half (48.1%) of chronic OA
pain pts were treated with at least 30 days of controlled opioids
annually with almost one in ten using SAOs as monotherapy for
long term management of their OA pain. Further analyses are
needed to better understand the appropriate and inappropriate
use of opioids in OA patients.
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OBJECTIVE: To evaluate long-term switching patterns
among anti-TNFs in patients with rheumatoid arthritis (RA).
METHODS: A retrospective study utilizing the PharMetrics
managed-care claims database was conducted. RA patients’ ﬁrst
anti-TNF encounter between January 1, 2000 and December 1,
2006 was identiﬁed. Patients were required to have 30
months of continuous plan eligibility; 6 months prior to and 24
months following their index date, as patients were
followed-up for 24 months after the index biologic date. Rates
of switching and days before switching were compared among
three cohorts based on their index biologic agent (inﬂiximab,
etanercept and adalimumab) plus methotrexate (MTX).
Univariate and multivariate statistical analyses were conducted
to determine if differences existed among the three cohorts.
RESULTS: Of 2155 patients analyzed, 605 (28.1%) received
inﬂiximab therapy, 1121 (52.0%) received etanercept therapy,
and 429 (19.9%) received adalimumab therapy; 75% were
female and the mean age was 49.5 years. Age, gender, Charlson
Comorbidity Index and disease staging were similar among the
three cohorts. During the 24 months follow-up, 376 patients
(17.4%) switched to another anti-TNF: 88 patients (14.5%) in
the inﬂiximab cohort switched compared to 203 (18.1%) in
etanercept group and 85 (19.8%) in the adalimumab group
(p = 0.0728). The mean time to switch for all patients was
342.1 days. The inﬂiximab group had an average time of 395.4
days, compared to 329.7 days in the etanercept group, and
321.0 days in the adalimumab group (P = 0.0173). After con-
trolling for demographic variables and disease severity, differ-
ences among the three cohorts were statistically signiﬁcant
(p < 0.05). CONCLUSION: Switching among therapies is an
important measure of the effectiveness of RA treatment. This
study found that, in a two-year follow-up period, inﬂiximab
plus MTX is associated with a lower switching rate and longer
time before switching, as compared to the other anti-TNFs.
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